Completed PHASE3 INTERVENTIONAL 4-arm NCT02578771

Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

Pilot Clinical Evaluation to Characterize the in Vivo Effects of Topically Applied ZuraPrep and ZuraPrep Vehicle

Sponsor: Zurex Pharma, Inc.

Interventions ChloraPrep CHG/IPA Teal Tint Normal Saline ZuraPrep with 70% IPA ZuraPrep without 70% IPA

Updated 8 times since 2017 Last updated: Jul 13, 2017 Started: Oct 31, 2015 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Surgical Site Infection, this trial is completed. The trial is conducted by Zurex Pharma, Inc. and has accumulated 8 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Aug 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zurex Pharma, Inc.

Data source: Zurex Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sterling, United States